Ertapenem
- Generic Name
- Ertapenem
- Brand Names
- Invanz, Ertapenem SUN
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N3O7S
- CAS Number
- 153832-46-3
- Unique Ingredient Identifier
- G32F6EID2H
- Background
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.
- Indication
Ertapenem is indicated to treat the following moderate to severe infections caused by susceptible bacteria in adult and pediatric patients (three months of age and older):
Ertapenem is also used in adults for the prophylaxis of surgical site infection following elective colorectal surgery.
- Associated Conditions
- Acute Gynecological Infection, Severe Community-acquired Pneumonia (sCAP), Surgical Site Infections, Acute, moderate Pelvic Infections caused by susceptible bacteria, Acute, severe susceptible bacteria Pelvic Infections, Moderate Community acquired pneumonia, Moderate Complicated Intra-Abdominal Infections (cIAIs) caused by susceptible bacteria, Moderate Diabetic Foot Infection, Moderate Gynaecological infection caused by susceptible bacteria, Moderate Postpartum Endomyometritis caused by susceptible bacteria, Moderate Septic Abortion caused by susceptible bacteria, Moderate complicated Urinary Tract Infection caused by susceptible bacteria, Moderate complicated skin and skin-structure infections caused by susceptible bacteria, Severe Complicated Intra-Abdominal Infections (cIAIs) caused by susceptible bacteria, Severe Diabetic Foot Infection, Severe Gynaecological infection caused by susceptible bacteria, Severe Postpartum Endomyometritis caused by susceptible bacteria, Severe Septic Abortion caused by susceptible bacteria, Severe complicated Urinary Tract Infection caused by susceptible bacteria, Severe complicated skin and skin-structure infections caused by susceptible bacteria
- Associated Therapies
- -
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 541
- Registration Number
- NCT01844856
PK/PD of Ertapenem In Patients With TB
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2017-08-25
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 12
- Registration Number
- NCT01730664
- Locations
- 🇳🇱
UMCG - Tuberculosis Center, Groningen, Netherlands
Antibiotics for Klebsiella Liver Abscess Study
- Conditions
- Interventions
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 152
- Registration Number
- NCT01723150
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore
🇸🇬Tan Tock Seng Hospital, Singapore, Singapore
Pharmacokinetics and Safety of Ertapenem in the Postpartum Period
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Daniel Benjamin
- Target Recruit Count
- 3
- Registration Number
- NCT01587495
- Locations
- 🇺🇸
DUMC, Durham, North Carolina, United States
Pharmacokinetics Ertapenem Burns
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT01497990
- Locations
- 🇫🇷
Nantes University Hospital, Nantes, France
Antibiotics Versus Surgery in Acute Appendicitis
- Conditions
- Interventions
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- A.O. Ospedale Papa Giovanni XXIII
- Target Recruit Count
- 218
- Registration Number
- NCT01421901
- Locations
- 🇮🇹
1St General Surgery Unit Papa Giovanni XXIII Hospital Bergamo, Bergamo, Italy
Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 565
- Registration Number
- NCT01370616
Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2012-01-02
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 100
- Registration Number
- NCT01297842
- Locations
- 🇹🇭
Siriraj Hospital, Bangkok, Thailand
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01265784
- Locations
- 🇧🇬
MHAT "Russe" AD, Russe, Russe, Bulgaria
🇺🇸Barnes Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸Long Beach VA Medical Center, Long Beach, California, United States
Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)
- Conditions
- Interventions
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 599
- Registration Number
- NCT01254344
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.